Kyverna Reports Q3 2026 Net Loss of $41.9 Million as SPS BLA Submission Is Completed

Kyverna reported a third-quarter 2026 net loss of $41.9 million, or $0.68 per share, and ended September with $170.6 million in cash, cash equivalents and marketable securities. The company completed its rolling BLA submission for miv-cel in stiff person syndrome (SPS), requesting priority review…